Select Page

Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
Kutz A, Kim D,Wexler D, Liu J, Schneeweiss S, Glynn R and Patorno E
Diabetes Care 2023;46(11):2004–2014

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function
Herold K, Gitelman S, Gottlieb P, Knetch L, Raymond R, and Ramos E
Diabetes Care. 2023 Oct 1;46(10):1848-1856